Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review

Arushi Kapoor; Kripa Balaram; Rajesh R Tampi; Shilpa Srinivasan

文献导航

搜索文章

搜索思路

钛学术文献服务平台 \
学术期刊 \
医药卫生期刊 \
神经病学与精神病学期刊 \
世界精神病学杂志期刊 \
Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review

作者：

Arushi Kapoor Kripa Balaram Rajesh R Tampi Shilpa Srinivasan

基本信息来源于合作网站，原文需代理用户跳转至来源网站获取

Pimavanserin

Alzheimer’s

disease

PSYCHOSIS

Psychotic

disorders

Antipsychotic

agents

摘要：

BACKGROUND Alzheimer’s disease(AD)is among the most prevalent forms of dementia in the world and neuropathological studies suggest similar high prevalence of mixed(AD+vascular)dementias.Approximately 25%-50%of individuals with AD develop psychosis sometime during their illness.The presence of psychosis in AD worsens outcomes.Currently there are no United States Food and Drug Administration(FDA)approved medications for the treatment of psychosis in AD.Pimavanserin,a novel atypical antipsychotic medication,was approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson disease psychosis and is currently in clinical trials for the treatment of psychosis in AD.AIM To evaluate the existing literature regarding the use of pimavanserin for treating psychosis among individuals with AD.METHODS A literature review of clinical studies of pimavanserin treatment for psychosis in individuals with AD was performed using the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines.Trials were identified by systematically searching PubMed,MEDLINE,EMBASE,Cochrane Central Register of Controlled Trials,Web of Science,and Scopus through October 2019.The 5-point Jadad scoring system was used to assess the methodologic quality of the randomized placebo-controlled trials.RESULTS A total of 499 citations were retrieved and pooled in EndNote and de-duplicated to 258 citations.This set was uploaded to Covidence for screening.Two separate screeners(Srinivasan S and Tampi RR)evaluated the titles,abstracts,and full text of eligible articles.Of the identified 258 abstracts,98 articles underwent full text review and 2 publications from 1 randomized controlled trial(RCT)were included in the final analysis.The quality of evidence was assessed to be of good methodologic quality,scoring 4 out of 5 using the 5-point Jadad questionnaire with the Jadad Scoring calculation.This systematic review found only one RCT that evaluated the use of pimavanserin for the treatment of psychosis among indivi

内容分析

关键词云

关键词热度

相关文献

推荐文献

根据相关规定，获取原文需跳转至原文服务方进行注册认证身份信息

完成下面三个步骤操作后即可获取文献，阅读后请点击下方页面【继续获取】按钮

钛学术文献服务平台

学术出版新技术应用与公共服务实验室出品

原文合作方

获取文献流程

1.访问原文合作方请等待几秒系统会自动跳转至登录页，首次访问请先注册账号，填写基本信息后，点击【注册】

2.注册后进行实名认证，实名认证成功后点击【返回】

3.检查邮箱地址是否正确，若错误或未填写请填写正确邮箱地址，点击【确认支付】完成获取，文献将在1小时内发送至您的邮箱

*若已注册过原文合作方账号的用户，可跳过上述操作，直接登录后获取原文即可

点击【获取原文】按钮，跳转至合作网站。

首次获取需要在合作网站进行注册。

注册并实名认证，认证后点击【返回】按钮。

确认邮箱信息，点击【确认支付】，订单将在一小时内发送至您的邮箱。

* 若已经注册过合作网站账号，请忽略第二、三步，直接登录即可。

期刊分类
期刊（年）
期刊（期）
期刊推荐

中国医学临床医学五官科学内科学医疗保健医药卫生总论基础医学外科学大学学报妇产科学与儿科学特种医学皮肤病学与性病学神经病学与精神病学肿瘤学药学预防医学与卫生学

世界精神病学杂志2021 世界精神病学杂志2020

世界精神病学杂志2020年第9期世界精神病学杂志2020年第7期世界精神病学杂志2020年第6期世界精神病学杂志2020年第5期世界精神病学杂志2020年第4期世界精神病学杂志2020年第3期世界精神病学杂志2020年第2期世界精神病学杂志2020年第12期世界精神病学杂志2020年第11期世界精神病学杂志2020年第10期世界精神病学杂志2020年第1期

按字母查找期刊：

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
其他

联系合作广告推广: shenyukuan@paperpass.com

篇名	Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
来源期刊	世界精神病学杂志	学科	医学
关键词	Pimavanserin Alzheimer’s disease PSYCHOSIS Psychotic disorders Antipsychotic agents
年，卷（期）	2020,（7）	所属期刊栏目
研究方向		页码范围	162-174
页数	13页	分类号	R74
字数		语种
DOI